AU2016317806B2 - Heteroaryl compounds and their use as therapeutic drugs - Google Patents

Heteroaryl compounds and their use as therapeutic drugs Download PDF

Info

Publication number
AU2016317806B2
AU2016317806B2 AU2016317806A AU2016317806A AU2016317806B2 AU 2016317806 B2 AU2016317806 B2 AU 2016317806B2 AU 2016317806 A AU2016317806 A AU 2016317806A AU 2016317806 A AU2016317806 A AU 2016317806A AU 2016317806 B2 AU2016317806 B2 AU 2016317806B2
Authority
AU
Australia
Prior art keywords
methyl
cyclopentyl
pyrazol
oxy
amino
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
AU2016317806A
Other languages
English (en)
Other versions
AU2016317806A1 (en
Inventor
Mi Yeon Jang
Hadong Kim
Jin Kwan Kim
Myeong-Seop Kim
Sumin Kim
Seong Jin Park
Taesun Park
Ki Moon Ryu
Joon-Ho SHEEN
Taeyoung Yoon
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
DONG-A SOCIO HOLDINGS Co Ltd
Original Assignee
DONG A SOCIO HOLDINGS CO Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by DONG A SOCIO HOLDINGS CO Ltd filed Critical DONG A SOCIO HOLDINGS CO Ltd
Publication of AU2016317806A1 publication Critical patent/AU2016317806A1/en
Application granted granted Critical
Publication of AU2016317806B2 publication Critical patent/AU2016317806B2/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4965—Non-condensed pyrazines
    • A61K31/497—Non-condensed pyrazines containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/78—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D213/81—Amides; Imides
    • C07D213/82—Amides; Imides in position 3
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Oncology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Hematology (AREA)
  • Communicable Diseases (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Pyridine Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
AU2016317806A 2015-08-31 2016-08-31 Heteroaryl compounds and their use as therapeutic drugs Active AU2016317806B2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201562212520P 2015-08-31 2015-08-31
US62/212,520 2015-08-31
PCT/KR2016/009743 WO2017039331A1 (en) 2015-08-31 2016-08-31 Heteroaryl compounds and their use as therapeutic drugs

Publications (2)

Publication Number Publication Date
AU2016317806A1 AU2016317806A1 (en) 2018-02-22
AU2016317806B2 true AU2016317806B2 (en) 2020-11-19

Family

ID=58188774

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2016317806A Active AU2016317806B2 (en) 2015-08-31 2016-08-31 Heteroaryl compounds and their use as therapeutic drugs

Country Status (21)

Country Link
US (3) US10125118B2 (enExample)
EP (1) EP3344613B1 (enExample)
JP (2) JP2018528189A (enExample)
KR (1) KR102663118B1 (enExample)
CN (1) CN108368083B (enExample)
AU (1) AU2016317806B2 (enExample)
BR (1) BR112018004065B1 (enExample)
CA (1) CA2995675C (enExample)
CL (1) CL2018000529A1 (enExample)
CO (1) CO2018002045A2 (enExample)
CR (1) CR20180184A (enExample)
ES (1) ES2799300T3 (enExample)
IL (1) IL257391B (enExample)
MX (1) MX387785B (enExample)
MY (1) MY199607A (enExample)
PE (1) PE20181017A1 (enExample)
PH (1) PH12018500432A1 (enExample)
RU (1) RU2723480C2 (enExample)
UA (1) UA126372C2 (enExample)
WO (1) WO2017039331A1 (enExample)
ZA (1) ZA201802033B (enExample)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2017039331A1 (en) 2015-08-31 2017-03-09 Dong-A Socio Holdings Co., Ltd. Heteroaryl compounds and their use as therapeutic drugs
SI3971177T1 (sl) 2016-07-20 2024-10-30 Novartis Ag Derivati aminopiridina in njihova uporaba kot selektivni zaviralci ALK-2
ES2903528T3 (es) 2016-10-10 2022-04-04 Dong A Socio Holdings Co Ltd Compuestos de heteroarilo y su uso como inhibidores de MER
GB201820458D0 (en) * 2018-12-14 2019-01-30 Heptares Therapeutics Ltd Ox1 antagonists
GB201901142D0 (en) 2019-01-28 2019-03-20 Heptares Therapeutics Ltd OX1 Antagonists
GB201905328D0 (en) * 2019-04-15 2019-05-29 Azeria Therapeutics Ltd Inhibitor compounds
CN115968289B (zh) 2020-06-16 2025-09-30 因赛特公司 用于治疗贫血的alk2抑制剂
WO2022065962A1 (ko) * 2020-09-28 2022-03-31 한국화학연구원 Mlkl 결합 또는 분해용 화합물 및 이들의 의약 용도
TWI893486B (zh) * 2022-10-20 2025-08-11 南韓商東亞Ｓｔ股份有限公司 稠合雙環化合物及其等作為mer及axl抑制劑的用途

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004054977A1 (en) * 2002-12-13 2004-07-01 Cytopia Pty Ltd Nicotinamide-based kinase inhibitors
US20040180905A1 (en) * 2003-03-11 2004-09-16 Pfizer Inc Novel pyrazine compounds as transforming growth factor (TGF) compounds

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20020151712A1 (en) 1999-09-14 2002-10-17 Nan-Horng Lin 3-pyrrolidinyloxy-3'-pyridyl ether compounds useful for controlling chemical synaptic transmission
GB0001930D0 (en) 2000-01-27 2000-03-22 Novartis Ag Organic compounds
AR042586A1 (es) 2001-02-15 2005-06-29 Sugen Inc 3-(4-amidopirrol-2-ilmetiliden)-2-indolinona como inhibidores de la protein quinasa; sus composiciones farmaceuticas; un metodo para la modulacion de la actividad catalitica de la proteinquinasa; un metodo para tratar o prevenir una afeccion relacionada con la proteinquinasa
WO2003093297A2 (en) * 2002-05-03 2003-11-13 Exelixis, Inc. Protein kinase modulators and methods of use
US8030336B2 (en) 2002-12-13 2011-10-04 Ym Biosciences Australia Pty Ltd Nicotinamide-based kinase inhibitors
US7361764B2 (en) 2004-07-27 2008-04-22 Sgx Pharmaceuticals, Inc. Pyrrolo-pyridine kinase modulators
WO2007011760A2 (en) 2005-07-15 2007-01-25 Kalypsys, Inc. Inhibitors of mitotic kinesin
EP2687533B1 (en) 2006-07-20 2017-07-19 Debiopharm International SA Acrylamide derivatives as FAB I inhibitors
US20140249135A1 (en) 2007-03-01 2014-09-04 Novartis Ag Pim kinase inhibitors and methods of their use
US9408873B2 (en) * 2010-08-23 2016-08-09 Kang Stem Biotech Co., Ltd. Pharmaceutical composition comprising stem cells treated with NOD2 agonist or culture thereof for prevention and treatment of immune disorders and inflammatory diseases
JP6012735B2 (ja) 2011-09-15 2016-10-25 エフ．ホフマン−ラ ロシュ アーゲーＦ． Ｈｏｆｆｍａｎｎ−Ｌａ Ｒｏｃｈｅ Ａｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ 新規ジヒドロキノリン−２−オン誘導体
WO2017039331A1 (en) 2015-08-31 2017-03-09 Dong-A Socio Holdings Co., Ltd. Heteroaryl compounds and their use as therapeutic drugs

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004054977A1 (en) * 2002-12-13 2004-07-01 Cytopia Pty Ltd Nicotinamide-based kinase inhibitors
US20040180905A1 (en) * 2003-03-11 2004-09-16 Pfizer Inc Novel pyrazine compounds as transforming growth factor (TGF) compounds

Non-Patent Citations (8)

* Cited by examiner, † Cited by third party
Title
CAPLUS ACCESSION NO. 1935:19785 & GRYSZKIEWICZ-TROCHIMOWSKI, E. Archiwum Chemji I Farmacji, 1934, 1, 65-71 (CAPLUS ABSTRACT) *
CAPLUS ACCESSION NO. 1949:13185 & CHARONNAT, R. et al. Bulletin de la Societe Chimique de France, 1948, 1014-1017 (CAPLUS ABSTRACT) *
PUBCHEM CID 55069206, Creation Date: 24 January 2012 *
PUBCHEM CID 60315064, Creation Date: 18 October 2012 *
PUBCHEM CID 60315178, Creation Date: 18 October 2012 *
PUBCHEM CID 62160816, Creation Date: 22 October 2012 *
PUBCHEM CID 63279265, Creation Date: 22 October 2012 *
PUBCHEM CID 64915258, Creation Date: 23 October 2012 *

Also Published As

Publication number Publication date
WO2017039331A1 (en) 2017-03-09
UA126372C2 (uk) 2022-09-28
ES2799300T3 (es) 2020-12-16
JP2018528189A (ja) 2018-09-27
NZ739648A (en) 2024-05-31
BR112018004065A2 (pt) 2018-10-02
AU2016317806A1 (en) 2018-02-22
RU2018111072A (ru) 2019-10-04
PH12018500432A1 (en) 2018-08-29
CN108368083B (zh) 2022-02-01
RU2723480C2 (ru) 2020-06-11
CN108368083A (zh) 2018-08-03
US12195446B2 (en) 2025-01-14
RU2018111072A3 (enExample) 2020-01-20
CL2018000529A1 (es) 2018-08-24
CR20180184A (es) 2018-08-23
EP3344613B1 (en) 2020-03-04
US10947215B2 (en) 2021-03-16
US20230002353A1 (en) 2023-01-05
ZA201802033B (en) 2022-07-27
IL257391B (en) 2021-05-31
JP2022058371A (ja) 2022-04-12
US20170355690A9 (en) 2017-12-14
US10125118B2 (en) 2018-11-13
CA2995675C (en) 2023-12-12
BR112018004065B1 (pt) 2023-12-12
EP3344613A1 (en) 2018-07-11
MX2018002574A (es) 2019-02-25
US20190119252A1 (en) 2019-04-25
PE20181017A1 (es) 2018-06-26
MY199607A (en) 2023-11-09
EP3344613A4 (en) 2019-01-23
JP7208348B2 (ja) 2023-01-18
CA2995675A1 (en) 2017-03-09
KR20180044995A (ko) 2018-05-03
US20170066742A1 (en) 2017-03-09
CO2018002045A2 (es) 2018-05-21
MX387785B (es) 2025-03-18
KR102663118B1 (ko) 2024-05-03
IL257391A (en) 2018-04-30

Similar Documents

Publication Publication Date Title
AU2016317806B2 (en) Heteroaryl compounds and their use as therapeutic drugs
AU2011249167B2 (en) Picolinamide and pyrimidine-4-carboxamide compounds, process for preparing and pharmaceutical composition comprising the same
TWI532727B (zh) 吡羧醯胺化合物
DK2597955T3 (en) QUINOLINE DERIVATIVES AND MILK INHIBITORS CONTAINING THESE
KR102644788B1 (ko) Erk1 및 erk2의 헤테로사이클릭 억제제 및 암 치료에서 이의 용도
EP3405192B1 (en) Bruton's tyrosine kinase inhibitors
CA2753434A1 (en) Soluble guanylate cyclase activators
BRPI0713578A2 (pt) composto, formulação farmacêutica, uso de um composto, métodos de prevenção e/ou tratamento de condições, de distúrbios, e de doenças, para aumentar a formação óssea, a densidade mineral óssea, e a incidência de fratura, e para melhorar a cicatrização de fratura, e, processo para preparar um composto
KR20150135794A (ko) 6-(5-히드록시-1h-피라졸-1-일)니코틴아미드 유도체 및 ｐｈｄ의 저해제로서의 그의 용도
EA010165B1 (ru) Производные индазола
TW201038554A (en) Nicotinamide derivatives, their preparation and their therapeutic application
AU2021242143B2 (en) Aminopyrimidine derivatives and their use as Aryl hydrocarbon receptor modulators
EP3681883A1 (en) Diphenyl derivatives and uses thereof
IL160874A (en) 4-imidazolin-2-one derivatives and pharmaceutical compositions containing the same
CN103492366B (zh) 伯胺二醇二氮烯鎓杂环衍生物
US10793566B2 (en) Bruton's tyrosine kinase inhibitors
HK1257578B (en) Heteroaryl compounds and their use as therapeutic drugs
HK1257578A1 (en) Heteroaryl compounds and their use as therapeutic drugs

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)